https://www.selleckchem.com/products/TWS119.html
85, 95% CI 0.37-1.97, P=.71, I =0%], and [POSs OR 0.52, 95% CI 0.19-12.01, P=.69, I =0%]). The risk of minor bleeding (P=.88) or stroke (P=.69) was comparable between the groups. UI-NOAC resulted in a significant reduction in silent stroke (SS) (OR 0.44, 95% CI 0.23-0.83, P=.01, I =72%). No significant difference was found in SS between once-daily and twice-daily NOACs (OR 0.91, 95% CI 0.63-1.33, P=.64, I =0%) in the MI-NOAC group. UI-NOAC, as a peri-procedural anticoagulation strategy for catheter ablation in AF, had similar safety comp